Mutations in the IDH1 gene often result in the production of an enzyme with a neomorphic activity, leading to the accumulation of an oncometabolite called 2-hydroxyglutarate (2-HG). This metabolite is implicated in the oncogenic process by altering the cellular epigenetic landscape, thus affecting gene expression and promoting tumorigenesis.
